The protein encoded by the neu protooncogene (human gene symbol NGL for neuro/glioblastoma-derived) is a member of the surface receptor/tyrosine kinase family. Though its structure suggests that it can transduce a transmembrane signal, neither its extracellular ligand nor its critical intracellular substrates are known. To explore the functional properties of the protein encoded by neu, we created a fusion gene that joins the cytoplasmic domain of neu to the extracellular portion of an immunoglobulin heavy chain. The localization of the fusion polypeptide can then be controlled by coexpression with immunoglobulin light chain. In the absence of light chain, the heavy chain-neu polypeptide is expressed intracellularly and has no transforming activity. By contrast, in the presence oflight chain the fusion polypeptide is expressed at the cell surface and produces tumorigenic foci. Thus, transformation apparently requires expression at the cell surface, where the neu intracellular domain can interact with components that are localized to the plasma membrane. The fusion protein is active in cellular transformation when the transmembrane domain is derived either from neu or from immunoglobulin, indicating that the neu transmembrane domain is not specifically required for transformation, although neu activation in tumors is known to result from a point mutation in this region. The extracellular immunoglobulin heavy and light chain domains of the fusion protein form a functional binding site that allows antigen to modulate its activity, reversing the transforming effect.
ABSTRACT
The protein encoded by the neu protooncogene (human gene symbol NGL for neuro/glioblastoma-derived) is a member of the surface receptor/tyrosine kinase family. Though its structure suggests that it can transduce a transmembrane signal, neither its extracellular ligand nor its critical intracellular substrates are known. To explore the functional properties of the protein encoded by neu, we created a fusion gene that joins the cytoplasmic domain of neu to the extracellular portion of an immunoglobulin heavy chain. The localization of the fusion polypeptide can then be controlled by coexpression with immunoglobulin light chain. In the absence of light chain, the heavy chain-neu polypeptide is expressed intracellularly and has no transforming activity. By contrast, in the presence oflight chain the fusion polypeptide is expressed at the cell surface and produces tumorigenic foci. Thus, transformation apparently requires expression at the cell surface, where the neu intracellular domain can interact with components that are localized to the plasma membrane. The fusion protein is active in cellular transformation when the transmembrane domain is derived either from neu or from immunoglobulin, indicating that the neu transmembrane domain is not specifically required for transformation, although neu activation in tumors is known to result from a point mutation in this region. The extracellular immunoglobulin heavy and light chain domains of the fusion protein form a functional binding site that allows antigen to modulate its activity, reversing the transforming effect.
The neu protooncogene encodes a cell surface glycoprotein highly homologous to the epidermal growth factor (EGF) receptor (EGFR). It has a cysteine-rich extracellular region, a single hydrophobic transmembrane domain, and an intracellular protein-tyrosine kinase domain (1, 2) . The neu gene was originally detected by DNA transfection assays as an oncogene present in rat neuroblastomas and glioblastomas, and in multiple independent tumors it was found to be activated by a point mutation that converts a valine residue to a glutamic residue in the encoded transmembrane domain (3) . In addition, an amplified copy number of the human homologue of the neu gene, NGL for neuro/glioblastomaderived, has been found in certain types of human tumor (4, 5) . Other oncogenes of the surface receptor/tyrosine kinase family include v-erbB, which encodes a truncated version of EGFR (6, 7) , and v-fms, which encodes a mutated form of the colony stimulating factor-1 receptor (8) .
Though the properties of the neu-encoded protein and its sequence homology with EGFR strongly suggest that it is a growth factor receptor, its ligand has not been identified. In addition, while its tyrosine kinase activity is likely to be involved in the transmission of a proliferative signal, the requirements for interaction of neu protein with phosphorylation substrates or other proteins involved in intracellular signal transmission are unknown.
To investigate the molecular requirements for neu signaling activity, we have constructed fusion proteins containing parts of the neu protein and parts of an Ig heavy (H) chain. Replacement of the extracellular and transmembrane domains of neu with the corresponding Ig H chain domains indicated that neither of these domains of neu is specifically required for oncogenic activity. In addition, by expression of the fusion polypeptide in the presence or absence of Ig light (L) chain, it was possible to control its intracellular localization, indicating that neu transforming activity requires expression at the cell surface. Finally, treatment with an antigen bound by the Ig portion of the fusion protein allowed the transforming capacity to be modulated.
MATERIALS AND METHODS
Construction of Recombinant Plasmids. Plasmids pSV2-IgH/neu and pSV2IgK (see Fig. 1 ) were made as follows. The promoters of the murine Ig VH and VK segments [H chain and K L chain variable (V) region genes] were deleted by BAL-31 digestion to, respectively, 34 or 17 nucleotides before the initiation codon and were replaced with simian virus 40 (SV40) transcription signals by ligating to the HindIII site of pSV2 with a synthetic linker. The murine VH and human Au H chain constant (C) region gene (CL) segments were joined by ligating HindIII sites flanking these segments, while the murine VK and human K L chain CK segments were similarly joined by ligating a Sac I site to an EcoRI site through a polylinker; in both cases this ligation eliminates the Ig gene enhancer. The Pvu II-BamHI fragment carrying the neo gene of pSV2-neo was ligated into pSV2IgK by using a polylinker between an Hha I site downstream of CK and the BamHI site in the pSV2 portion. To produce the Ig H chain gene/neu fusion point, a synthetic double-stranded oligonucleotide was used as a bridge between a Sac I-Hae II fragment containing the portion of membrane-associated exon Mu1 that encodes the extracellular segment of IgM and a BspMII-Bal I fragment containing cDNA encoding the cytoplasmic region of neu. Two versions of this oligonucleotide were made, encoding a fusion of Phe-38 of M1.u to Lys-681 of neu, or Glu-12 of Mul to Phe-658 of neu, thus yielding pSV2IgH/neu-TM~g and pSV2IgH/neu-TMneu' which code for the transmembrane domains of Ig or neu. This Sac I-Bal I fusion fragment was ligated by using a polylinker into pSV2IgH/neu between the same Sac I site ofthe Ig portion and the BgI II site ofthe pSV2 portion.
Abbreviations: H, heavy; L, light; EGF, epidermal growth factor; EGFR, EGF receptor; P-Cho, phosphocholine; V, variable; SV40, simian virus 40; C, constant; KLH, keyhole limpet hemocyanin.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
8058
Cell Biology: Flanagan and Leder Cell Culture and Transfection. Murine 3T3 fibroblasts were maintained in Dulbecco's modified Eagle's medium with 10% (vol/vol) fetal calf serum. For each transfection, 106 cells on a 10-cm plate were treated by the calcium phosphate precipitation technique (9) , with 25 1Lg of calf thymus carrier DNA and 2 gg of linearized pSV2IgK DNA or equimolar amounts of the other plasmids. After 24 hr each plate was split into four plates, two of which were allowed to form foci for 3 weeks in 5% fetal calf serum, while the other two were incubated with 0.4 mg of G418 per ml to select resistant colonies. To assess tumorigenicity, nude mice were injected subcutaneously with 106 cells of an uncloned G418-selected population and inspected weekly for tumors.
Metabolic Labeling and Immunoprecipitation. Subconfluent BALB/c 3T3 fibroblasts in 60-mm dishes were labeled with 100 gCi of[35S]methionine (New England Nuclear, 1000
Ci/mmol; 1 Ci = 37 GBq) in 2 ml of methionine-free medium for 16 hr or with 500 gCi of 32p; (New England Nuclear, 1 Ci/mmol) in 2 ml of phosphate-free medium for 4 hr. The cells were lysed in 1% Triton X-100/10 mM Hepes, pH 7.5/1 mM phenylmethylsulfonyl fluoride/1% aprotinin (Sigma), also containing 10 mM NaF and 1 mM sodium vanadate for 32p;labeled cells. After the lysates were centrifuged at 10,000 x g for 10 min, polypeptides were immunoprecipitated by incubating with affinity-purified goat polyclonal antibodies (Southern Biotechnology Associates, Birmingham, AL) for 1 hr at 4°C, followed by protein A-Sepharose beads (Pharmacia) for 1 hr at 4°C. The beads were then washed three times in 0.2% Triton X-100/0.1% NaDodSO4/600 mM NaCI/10 mM Tris HCI, pH 8, and three times in the same buffer containing 150 mM NaCl. The beads were heated at 100°C for 2min in sample buffer, and proteins were separated on NaDodSO4/polyacrylamide gels.
Rosetting Assay. Sheep erythrocytes were coupled with diazophenylphosphocholine as described (10) . Rosettes were formed by incubating dishes of 3T3 fibroblasts with 0.1% erythrocytes in phosphate-buffered saline containing 5% fetal calf serum for 1 hr at room temperature and then washing off the excess erythrocytes.
Immunofluorescence. Analysis of cell surface immunofluorescence was performed by flow cytometry on an Ortho Diagnostics Cytofluorograf-TI. Subconfluent BALB/c 3T3 fibroblasts were washed with phosphate-buffered saline and then suspended in phosphate-buffered saline containing 5 mM EDTA. The cells were stained with biotinylated monoclonal antibody DA4.4, which binds human Ig ,u chain (11) followed by fluorescein-labeled avidin (Zymed Laboratories, Burlingame, CA). For immunofluorescence of permeabilized cells, 3T3 fibroblasts were grown on glass chamber slides (Miles), then fixed for 5 min in methanol, and stained with affinity-purified goat polyclonal antibody against human Ig ,u chain (Southern Biotechnology Associates).
RESULTS
Plasmid pSV2IgH/neu was constructed by joining an Ig ,u chain gene to the normal, unmutated rat c-neu cDNA, as shown in Fig. la . The plasmid was made in two versions, pSV2IgH/neu-TM~g and pSV2lgH/neu-TMneu encoding, respectively, the transmembrane domain of Ig or neu (the designation pSV2IgH/neu is used here to include both versions when it is not necessary to distinguish them). Fig. lb shows the Ig K L chain construct pSV2IgK. The Ig V regions are those expressed in the phosphocholine (P-Cho)-binding antibody of myeloma S107. Both pSV2IgH/neu and pSV2IgK have the Ig gene promoter and enhancer deleted and replaced by SV40 early transcription signals; this allows them to be expressed in fibroblasts, a cell type especially convenient for assessment of growth stimulation and transformation. Fig. 2a shows a gel analysis of metabolically (12) . The full length of pSV2 is not shown, as indicated by double slashes. Ig coding sequences are shown by black boxes; in both plasmids the V segment is from P-Cho-(PC)-binding mouse myeloma S107 (13) , and the C segment is from human DNA (14, 15) . Sequences from normaL, nonactivated rat neu cDNA (3) A band at 150 kDa was also seen after 32pi-labeling ( Fig. 2a , lanes 4 and 5), indicating that, like the normal neu protein (2), the hybrid polypeptide is phosphorylated in vivo.
To assess the cell surface expression of the hybrid proteins, transfected fibroblasts were tested for the ability to bind erythrocytes coupled to the P-Cho hapten. Both pSV2IgH/neu-TMTgand pSV2lgH/neu-TMn,,, cotransfected with pSV2IgK, gave a positive result in this rosetting assay (Fig. 3a) : after selection of transfected colonies with G418, respectively =40% and =60% of the colonies formed distinct rosettes. This shows that the Ig H chain-neu fusion polypeptide can assemble correctly with the Ig L chain to form a functional hapten-binding receptor that is expressed at the surface of the fibroblasts. The transfected fibroblasts were also tested by surface immunofluorescence by using a monoclonal antibody that binds Ig Thus, expression of the Ig H chain-neu fusion polypeptide at the cell surface is apparently dependent on the presence of Ig L chain.
To examine whether the lack of cell surface expression might be due to rapid intracellular degradation, the quantities of fusion polypeptide were examined by immunoprecipita- (Fig. 2b) . The results show that the Ig H chain-neu polypeptide is not destabilized in the absence of L chain; in fact, somewhat more fusion polypeptide was detected in cells without Ig L chain (Fig. 2b, lanes 3 and 4) than in cells expressing L chain (Fig. 2b, lanes 1 and 2) . Examination of the intracellular localization of the Ig H chain-neu polypeptide in the absence ofL chain, by immunofluorescent staining of permeabilized cells, revealed a distribution characteristic of the endoplasmic reticulum (Fig. 3b ).
The in vitro transforming activity of the hybrid proteins was tested by focus assays using BALB/c 3T3 fibroblasts. The pSV2IgH/neu fusion plasmids transformed strongly when transfected together with the pSV2IgK L chain plasmid: stained foci are shown in Fig. 4a , and the efficiency of focus formation is indicated in Fig. 4c . All foci formed rosettes with P-Cho-coupled erythrocytes, showing that the complete hybrid receptor was on the surface of the transformed cells. No foci were seen after transfection with pSV2-IgK alone, with pSV2IgK plus pSV2IgH (a plasmid encoding a normal Ig H chain), or with pSV2neuN (a plasmid bearing the complete normal, unmutated neu cDNA) ( Fig. 4c ). Furthermore, no foci were seen when the pSV2IgH/neu plasmids were transfected in the absence of pSV2IgK, showing that transformation requires the presence of Ig L chain (Figs. 4 b and c) . The efficiency of transformation by pSV2IgH/neu plus pSV2IgK was comparable to that of pSV2neuNT, a plasmid that carries the complete neu cDNA with the activating mutation that occurs in rat neuroblastomas and glioblastomas (3) (Fig. 4c ).
The ratio of foci to G418 colonies is somewhat lower for pSV2IgH/neu plus pSV2IgK than for pSV2neuNT, but this is probably due at least in part to the requirement for expression of two polypeptides for transformation by pSV2IgH/neu with pSV2IgK, whereas transformation by pSV2neuNT requires only one. In size and microscopic appearance, the foci pro- duced by pSV2IgH/neu plus pSV2IgK were indistinguishable from those given by pSV2neuNT (data not shown).
To assess tumorigenic potential of the Ig-neu hybrid, transfected NIH 3T3 fibroblasts were injected subcutaneously into immunodeficient nude mice. Both pSV2IgH/neu-TMIg and pSV2Ig/neu-TMneu, cotransfected with pSV2IgK, gave rapidly-growing tumors that were detectable within 1 week in all mice, whereas no tumors appeared after transfection of pSV2IgK with pSV2IgH ( Fig. 4d ). pSV2neuN yielded tumors that grew much more slowly in two of three mice (Fig. 4d ), although this plasmid was inactive in focus assays in BALB/c 3T3 cells (Fig. 4c ) and NIH 3T3 cells (unpublished data and ref.
2). A very weak transforming capacity of pSV2neuN would be compatible with reports of transformation by the unmutated human neu homologue when expressed at very high levels (16) .
Since the hybrid proteins were designed to bind P-Cho, we tested the effects of P-Cho antigens on their signaling properties. Fig. 5 shows the effect on transfected BALB/c 3T3 cells of P-Cho coupled to keyhole limpet hemocyanin (P-Cho-KLH). P-Cho-KLH at concentrations as low as 0.01 ,ug/ml caused a reduced density ofgrowth in cells transfected with pSV2IgH/neu-TMIg orpSV2IgH/neu-TMneu plus pSV2-IgK (Fig. 5 ). There was also a reversion of the transformed (3) . pSV2IgH is the same as pSV2IgH/neu, except that it contains the normal Ig A chain membrane-associated exons and poly(A) site. pSV2-neo confers resistance to G418 (12) . The other plasmids are described in Fig. 1. (d) Tumor formation in nude mice after subcutaneous injection of transfected NIH 3T3 fibroblasts. Values are the number of mice with tumors per total number of mice. appearance of these cells (spindle-shaped and refractile) to a more normal, flattened state (data not shown). There was no effect on cells transfected with pSV2IgK plus pSV2IgH or with pSV2neuNT ( Fig. 5 ).
DISCUSSION
In the presence of Ig L chain, the hybrid Ig H chain-neu polypeptide transforms 3T3 fibroblasts strongly, apparently The effect of P-Cho-KLH antigen on fibroblasts transformed by the Ig-neu hybrid receptor. After G418-selection of transfected BALB/c 3T3 fibroblasts, uncloned cell populations were plated at one-fourth confluence in 3.5-cm diameter wells and were allowed to grow to confluence in 10o fetal calf serum. The medium was then changed to 5% serum containing various concentrations of P-Cho-KLH (shown at the top of each column in ,ug/ml) and was renewed every 3 days. After 8 days the cells were stained with methylene blue. as a result of the activity of the neu transforming potential. It is interesting that the pSV2IgH/neu-TMtg-encoded protein can transform, considering that both its extracellular and transmembrane domains are from Ig. This is compatible with other work on tyrosine kinase receptors, indicating that the extracellular domains are not essential for activity (6, 7, 17, 18) . In addition, it indicates that the neu transmembrane domain is not specifically required for transformation, even though the point mutation that activates neu in rat tumors is within this domain (3) .
How might fusion with Ig induce the transforming ability of neu? One possibility is that an activating conformational change is conveyed through the transmembrane a-helix. Alternatively, replacement of the extracellular domains may remove a negative control effect from the tyrosine kinase domain. Indeed, deletion of the extracellular domains of EGFR, which is very closely related to neu (1), may contribute to the activation of the v-erb-B oncogene (6, 7) . A comparable deletion of the neu extracellular region may cause weak activation (17) . Finally, ligand-induced clustering of perhaps as few as two receptor subunits has been proposed as the transmembrane signaling mechanism for many cell surface receptors (7, 11, (18) (19) (20) (21) , including the monomeric EGFR. Therefore, it is possible that in the Ig-neu hybrid receptor, formation of a dimer by the extracellular Ig H chain domains activates the neu portion by bringing together pairs of neu domains.
Low concentrations of an antigen bound by the Ig-neu hybrid receptor caused transformed 3T3 fibroblasts to revert to a more normal phenotype. This effect could be due to a diminished amount of receptor at the cell surface if, like other receptors (7) , the Ig-neu hybrid undergoes ligand-induced internalization. Indeed, a reversion of transformed phenotype accompanied by neu protein internalization has been reported to occur when 3T3 fibroblasts transformed by the intact neu oncogene are treated with an anti-neu antibody (22) . The reversion of transformation caused here by antigen Proc. Natl. Acad. Sci. USA 85 (1988) could alternatively be due to a negative signal being transmitted to the receptor's intracellular domains, mediated by changes in receptor conformation or clustering. In addition, it is noteworthy that formation oflarge numbers ofcomplexes of EGF with its receptor result in high tyrosine kinase activity and can inhibit cell proliferation (23) . Therefore, it is also possible that the reversion of transformation that we observed could be due to a hyperactivation of the hybrid Ig-neu receptor.
The presence of Ig L chain was essential for transformation by the Ig H chain-neu fusion polypeptide. In the absence of L chain, the amount of fusion polypeptide within the cell was not reduced, but it did not reach the cell surface and apparently was retained in the endoplasmic reticulum. [A comparable phenomenon of retention in the endoplasmic reticulum is seen when normal Ig H chain is expressed in pre-B-lymphocytes in the absence of L chain (24) .] Thus, transformation by the Ig H chain-neu polypeptide apparently requires expression at the cell surface. This finding implies that, in order to transmit a growth signal, the neu cytoplasmic domain may need to interact with phosphorylation substrates or other components that are not free in the cytosol or located in intracellular membranes such as the endoplasmic reticulum but rather are localized to the plasma membrane. For example, possible candidates for such components with an appropriate intracellular localization would include products of the ras and src oncogene families (25) . It is interesting that there is evidence to suggest that the v-fmsencoded protein may require transport to the cell surface to have a transforming effect (26, 27) , raising the possibility that this may be a general feature of the mechanism by which receptors with tyrosine kinase activity send signals into the interior of the cell.
The requirement found here for an Ig L chain gene as well as the Ig H chain-neu fusion gene provides an unusual example of cooperation for transformation. While cooperation between oncogenes has been observed previously (28, 29) , here the two encoded polypeptides associate to form a single protein, and one of them has no direct signaling function. The existence of a transforming gene that is undetectable in assays except when a specific complementary gene is expressed has general implications and suggests the possibility of a class of dominantly acting oncogenes that are difficult to detect by conventional assays. In addition, the requirement for L chain, which allows the fusion polypeptide to reach the cell surface, shows that genes that cooperate in transformation can be ancillary to the central biochemical transforming process.
Finally, our results raise the question of whether tumorigenesis in humans may sometimes involve the production of hybrid proteins with Ig fused to growth factor receptors. Other oncogenic fusion proteins have been detected in tumors (30) (31) (32) (33) . Furthermore, there are many reports of chromosomal translocations in tumors involving band 14q32, which contains the IGH locus (34) . In particular, it is intriguing that a study of B-cell chronic lymphocytic leukemias, which carry surface Ig, tentatively identified a set of translocations that joined band 14q32 to band 17q23 (35) near the assigned position of the human neu homologue (36) .
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